Mostrando 2 resultados de: 2
Frequency of CYP2C9 (*2, *3 and IVS8-109A>T) allelic variants, and their clinical implications, among mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin
ArticleAbstract: The majority of Mexican patients with diabetes mellitus type 2 (DMT2) (67.9-85.0%) are prescribed suPalabras claves:Cytochrome P450 2C9, DIABÉTES, Glibenclamide, Glycated hemoglobin A1c, MetforminAutores:Adrián LLerena, Castillo-Nájera F., Cuautle-Rodríguez P., de Andrés F., Molina-Guarneros J.A., Rodríguez-Rivera N.S.Fuentes:scopusPharmacogenetics of Metformin Transporters Suggests No Association with Therapeutic Inefficacy among Diabetes Type 2 Mexican Patients
ArticleAbstract: Mexico has been under official epidemiological alert due to diabetes since 2016. This study presentsPalabras claves:Diabetes type 2, Metformin, pharmacogenetics, sulphonylureas, therapeutic inefficacy, TransportersAutores:Adrián LLerena, de Andrés F., Espinosa-Sánchez A.G., Molina-Guarneros J.A., Ortega-Ayala A., Pérez-Silva E., Rodríguez-Rivera N.S.Fuentes:scopus